Indoran Injection

INDORAN inhibit gastric acid secretion through H2-receptor inhibition of gastric wall (gastric parietal cells) (see figure Channels tract) inhibition effect occurs at noon & night (basal) also can inhibit gastric acid secretion due to stimulation of the food, histamine & Pentagastrin; & slightly inhibit the secretion of pepsin (pepsin menginaktif) Me ^; secretion of sialic acid (a glycoprotein in gastric mucus) ->; is sitoprotektif 

Composition:

Each ml contains: ranitidine 25 mg

Each 2 ml ampoule berisis INDORAN ® injection 50 mg / ampoule

Indications:

Gastric & duodenal ulcer Hiperasiditas accompanying gastritis, Zollinger Ellison Syndrome (Sze) or severe stress -> especially if therapy can not be done orally

Dosage:

Adult

IM Injection: 50 mg (2 ml) can be repeated every 6-8 hours (do not need to be diluted)

Intravenous injection

Intermittent bolus: 50 mg (2 ml) can be repeated every 6-8 hours. Dilute INDORAN ® injection 50 mg to a solution of sodium chloride injection (0.9%) or other appropriate IV solution, up to levels not more than 2.5 mg / ml (20 ml). Give the infusion speed of not more than 4 ml / min (for 5 minutes).

Intermittent infusion: 50 mg (2 ml) can be repeated every 6-8 hours. Dilute INDORAN ® injection 50 mg to a solution of Dextrose Injection (5%) or other appropriate IV solution, up to levels not more than 0.5 mg / ml (100 ml). Give the infusion speed is not more than 5-7 ml / min (over 15.20 minutes).

Some patients who require increased doses, then given a dose (50 mg) more often, but not more than 400 mg / day.

Continuous intravenous injection:

Add INDORAN injection into the injection Dextrose solution (5%) or other appropriate infusion solution. Give the speed of 6.25 mg / hour. For example: 150 mg / 6 ml, injectable solution INDORAN ® in 250 mg Injection Dextrose solution (5%), given 10.7 ml / hour.

For patients Sze: INDORAN injection into a dilute solution of Dextrose Injection (5%) or other appropriate IV solution to levels not more than 2.5 mg / ml.

In patients with renal failure:

When creatin clearance (CC) <50 ml / min, 50 mg every 18-24 hours.

If needed, ranitidine levels in the blood circulation will be reduced, dose reduction should be done so that the time of dosing to coincide with the end of hemodialysis.

Side effects:

Pain is temporary after IM injection at the injection site; a burning sensation while, after IV injection. Fatigue (malaise), headache, drowsiness, insomnia, vertigo, agitation, depression and hallucinations have been reported, especially elderly patients are seriously ill. Arthralgia and myalgia Impaired heart rate have also been reported Gastrointestinal: constipation, diarrhea, nausea, vomiting, abdominal pain, pancreatitis. Me  ALT, hepatitis, hepatocellular or hepatocanalicular. Endocrine: gynecomastia, impotence, loss of libido, alopecia. Hypersensitivity reaction, anaphylaxis, edema angioneurotik.

Warning

Patients with impaired renal function the dose reduced.

Pregnancy or breast-feeding should be avoided unless it is needed or under the supervision of a doctor.

In patients with hepatic dysfunction with stringent safety monitoring in children is not known with certainty. In the IV injection at a dose> 100 mg 4 times daily for 5 days or more, should check SGPT, (starting day 5) than the rest of iv therapy

Avoid in patients with a history of acute porphyria.